Literature DB >> 25707773

Pro-protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain.

T A Walton1, S Nishtar2, P J Lumb3, M A Crook3, M S Marber4, J Gill4, A S Wierzbicki3.   

Abstract

OBJECTIVE: To determine the relationship between proprotein convertase subtilisin kexin 9 (PCSK9) levels and atheroma burden in Pakistanis presenting to an ambulatory centre with chest pain.
METHODS: A prospective matched case-control study of 400 patients selected for presence/absence of angiographic disease referred between 2001 and 2003. A comprehensive cardiovascular disease risk factor profile was assessed including demographics, environmental and biochemical risk factors including insulin resistance and PCSK-9 levels. Coronary atheroma burden was quantified by Gensini score.
RESULTS: In this population, PCSK-9 levels were weakly correlated (r = 0.23) with male gender (p = 0.06) and number of diabetes years (p = 0.09), and inversely with log10 of lipoprotein (a) concentration (p = 0.07) but not LDL-C. In multiple regression analysis, Gensini score was associated with age (p = 0.002), established angina (p = 0.001), duration of diabetes (p = 0.05), low HDL-C (p < 0.001), lipoprotein (a) (p = 0.01), creatinine (p < 0.001), C-Reactive Protein (p = 0.02) and PSCK-9 (p = 0.05) concentrations. PCSK9 added to the regression model. Neither total cholesterol nor LDL-C were significant risk factors in this study.
CONCLUSIONS: Proprotein convertase subtilisin kexin 9 concentrations are correlated with atheroma burden in Indian Asian populations from the sub-continent, not taking statin therapy, independent of LDL-C or other CVD risk factors.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25707773     DOI: 10.1111/ijcp.12615

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  4 in total

1.  Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.

Authors:  Hagai Tavori; Ilaria Giunzioni; Irene M Predazzi; Deanna Plubell; Anna Shivinsky; Joshua Miles; Rachel M Devay; Hong Liang; Shirya Rashid; MacRae F Linton; Sergio Fazio
Journal:  Cardiovasc Res       Date:  2016-03-15       Impact factor: 10.787

2.  Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV.

Authors:  Markella V Zanni; Lauren A Stone; Mabel Toribio; Dodie E Rimmelin; Jake Robinson; Tricia H Burdo; Kenneth Williams; Kathleen V Fitch; Janet Lo; Steven K Grinspoon
Journal:  Open Forum Infect Dis       Date:  2017-10-14       Impact factor: 3.835

Review 3.  New developments in atherosclerosis: clinical potential of PCSK9 inhibition.

Authors:  Ilaria Giunzioni; Hagai Tavori
Journal:  Vasc Health Risk Manag       Date:  2015-08-24

4.  PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.

Authors:  Krzysztof Jaworski; Piotr Jankowski; Dariusz A Kosior
Journal:  Arch Med Sci       Date:  2017-01-19       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.